BR112023002464A2 - Métodos e composições para estimular células t gama delta - Google Patents

Métodos e composições para estimular células t gama delta

Info

Publication number
BR112023002464A2
BR112023002464A2 BR112023002464A BR112023002464A BR112023002464A2 BR 112023002464 A2 BR112023002464 A2 BR 112023002464A2 BR 112023002464 A BR112023002464 A BR 112023002464A BR 112023002464 A BR112023002464 A BR 112023002464A BR 112023002464 A2 BR112023002464 A2 BR 112023002464A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
cells
gamma delta
stimulating
Prior art date
Application number
BR112023002464A
Other languages
English (en)
Inventor
Copik Alicja
Oyer Jeremiah
Dieffenthaller Thomas
Parks Griff
Original Assignee
Univ Central Florida Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Central Florida Res Found Inc filed Critical Univ Central Florida Res Found Inc
Publication of BR112023002464A2 publication Critical patent/BR112023002464A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODOS E COMPOSIÇÕES PARA ESTIMULAR CÉLULAS T GAMA DELTA. A presente invenção se refere a composições e métodos para estimular a expansão de células Tyo e citotoxicidade. São descritas composições terapêuticas e métodos usando célula Tyo estimuladas e expandidas.
BR112023002464A 2020-08-12 2021-08-12 Métodos e composições para estimular células t gama delta BR112023002464A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063064832P 2020-08-12 2020-08-12
PCT/US2021/045643 WO2022036024A2 (en) 2020-08-12 2021-08-12 Methods and compositions for stimulating gamma delta t cells

Publications (1)

Publication Number Publication Date
BR112023002464A2 true BR112023002464A2 (pt) 2023-05-02

Family

ID=80247373

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002464A BR112023002464A2 (pt) 2020-08-12 2021-08-12 Métodos e composições para estimular células t gama delta

Country Status (11)

Country Link
US (1) US20240010976A1 (pt)
EP (1) EP4196133A2 (pt)
JP (1) JP2023544240A (pt)
KR (1) KR20230048046A (pt)
CN (1) CN116529360A (pt)
AU (1) AU2021324767A1 (pt)
BR (1) BR112023002464A2 (pt)
CA (1) CA3189137A1 (pt)
IL (1) IL300530A (pt)
MX (1) MX2023001792A (pt)
WO (1) WO2022036024A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案
CN115282147A (zh) * 2022-08-31 2022-11-04 深圳市宝安区人民医院 罗拉匹坦或/和罗拉匹坦衍生物在抗结核分枝杆菌药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197347A1 (en) * 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
CA3127459A1 (en) * 2019-01-24 2020-07-30 University Of Central Florida Research Foundation, Inc. Compositions and methods for stimulating natural killer cells

Also Published As

Publication number Publication date
CN116529360A (zh) 2023-08-01
WO2022036024A3 (en) 2022-03-10
EP4196133A2 (en) 2023-06-21
WO2022036024A2 (en) 2022-02-17
MX2023001792A (es) 2023-03-10
AU2021324767A1 (en) 2023-04-13
KR20230048046A (ko) 2023-04-10
JP2023544240A (ja) 2023-10-23
US20240010976A1 (en) 2024-01-11
WO2022036024A9 (en) 2022-04-07
IL300530A (en) 2023-04-01
CA3189137A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
BR112023002464A2 (pt) Métodos e composições para estimular células t gama delta
BR112021013971A2 (pt) Composições e métodos para estimular células natural killer
AU2018262698A1 (en) Expansion of gamma delta T cells, compositions, and methods of use thereof
DOP2019000030A (es) Inhibidores de cdk2/4/6
EA202191559A1 (ru) Модифицированные аминовые липиды
DK1623017T3 (da) Frembringelse og isolering af antigenspecifikke T-celler
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
AR052238A1 (es) Formulacion de tabletas estables
MX339624B (es) Composiciones mejoradas de celulas y metodos para preparar las mismas.
ECSP20034868A (es) Conjugados anticuerpo anti-cd40-fármaco
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
GT200500113A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
BR112021024657A2 (pt) Célula de bacillus não esporulada, uso da referida célula, oligossacarídeo fucosilado, bem como o método para a produção e uso do mesmo e composição nutricional
BR112022000876A2 (pt) Anticorpos imunomoduladores e métodos de uso destes
CL2021002141A1 (es) Anticuerpos claudina 6 y usos de los mismos.
IL311307A (en) Alternative generation of human allogeneic T cells
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
DK1530628T3 (da) Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
MX2021016050A (es) Formulaciones transdermicas.
MX2020011470A (es) Metodos de terapia genica.
MX2022012990A (es) Proceso para generar células t autólogas modificadas genéticamente.
BR112021010804A2 (pt) Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
EA202092736A1 (ru) Производные простагландина f2альфа для снижения внутриглазного давления